New hope for children with rare growth disorder
NCT ID NCT03882034
Summary
This study tested whether the drug pegvisomant could safely control excess growth hormone in children with gigantism, a rare condition causing abnormal growth. Twelve children and teens, for whom standard treatments hadn't worked, received daily injections of the drug for one year. Researchers measured changes in growth rate, hormone levels, symptoms, and heart health to see if the treatment was effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITUITARY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.